Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination

Authors: Widge, AT., Rouphael, NG., Jackson, LA., Anderson, EJ., Roberts, PC., Makhene, M, Chappell, JD., Denison, MR., Stevens, LJ., Pruijssers, AJ., McDermott, AB., Flach, B, Lin, BC., Doria-Rose, NA., O’Dell, S, Schmidt, SD., Neuzil, KM., Bennett, H, Leav, B, Makowski, Mat, AJ, Cross, K, Edara, VV, Floyd, K, Suthar, MS., Buchanan, WL, CJ., Ledgerwood, JE., Mascola, JR., Graham, BS., and Beigel, JH.

Publication: New England Journal of Medicine; November 2020

Affiliations: National Institute of Allergy and Infectious Diseases (NIAID) ; Emory University of Medicine Decatur; Moderna Cambridge, MA; NIAID Bethesda, MD

Abstract: We recently reported the results of a phase 1 trial of a messenger RNA vaccine, mRNA-1273, to prevent infection with SARSCoV-2; those interim results covered a period of 57 days after the first vaccination.1,2 Here, we describe immunogenicity data 119 days after the first vaccination (90 days after the second vaccination) in 34 healthy adult participants in the same trial who received two injections of vaccine at a dose of 100 ug. The injections were received 28 days apart. The recipients were stratified according to age (18 to 55 years, 56 to 70 years, or ≥71 years), and the assays used have been described previously.1,2